44 Cook Street
56 articles about Cerecin Inc.
Cerecin forges strategic partnership with A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders.
Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, is pleased to announce the establishment of a Memorandum of Understanding with A*STAR's Institute of Molecular and Cell Biology.
Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, announced the in-license of CER-022 from the University of Alberta.
Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023
Cerecin Inc. announced that new data on investigational CER-0001 in infantile spasms has been accepted for presentation at the 35th International Epilepsy Congress, held in Dublin, Ireland from September 2nd-6th 2023.
Clinical Trial Data of Novel Metabolic Mechanism in Migraine: CER-0001, a Ketogenic Investigational Agent
Cerecin Inc. presented encouraging findings from a recent study on CER-0001, an investigational ketogenic agent, indicating that certain individuals suffering from migraines may experience benefit.
The Biotechnology Innovation Organization, Passage Bio and Palisade Bio saw leadership shakeups at the top, while Maze Therapeutics, Cerecin and more appointed new chief medical officers.
Cerecin, an innovative biopharmaceutical company focused on brain health, announced that Joseph S. Zakrzewski has joined the Company’s Board of Directors as Chairman.
Cerecin strengthens its leadership position in CNS drug development by adding a biotech veteran to the executive team
Bruce Morimoto joins Cerecin as Vice President of Drug Development
Cerecin continues to strengthen its experienced team in Asia Pacific as it accelerates clinical development plans
With the latest major Phase 3 failure of Biogen and Eisai’s beta-amyloid-targeting antibody drug aducanumab, researchers are increasingly turning to other drug targets for Alzheimer’s disease.
Accera closes new investment led by Asia's leading agribusiness group, Wilmar, and rebrands as Cerecin
Cerecin announces first close of a new investment round and establishment of new global HQ in Singapore
Apotheker Group Executive Search and Advisory Services Firm Celebrates its Launch and Honors Recently Appointed ACMA Board of Governors
Apotheker Group, Search and Advisory, an Executive Search & Advisory firm specializing in the life sciences industry, is hosting an invite-only event on Thursday, October 4th, 2018 at the Dream Downtown Hotel in Manhattan, NY to celebrate its recent launch as well as the newly appointed ACMA Board of Governors.
Accera Enters Into A Strategic Partnership And Exclusive Licensing Agreement With DuChemBio For Accera's Technology In Korea
Accera, Inc. Completes Enrollment Of Phase 3 NOURISH AD Study Of AC-1204 For The Treatment Of Alzheimer's Disease